转运蛋白与慢性肾脏病中的线粒体功能障碍
本研究探讨转运蛋白(TSPO)在慢性肾脏病(CKD)进展中的作用。在小鼠单侧输尿管梗阻和缺血再灌注损伤模型中,肾小管特异性敲除TSPO或使用TSPO拮抗剂PK11195可减轻肾损伤、炎症和纤维化。机制上,TSPO缺失通过破坏HK2介导的糖酵解并增强线粒体能量代谢发挥保护作用。
要点
- TSPO在CKD患者及小鼠损伤肾小管中表达上调。
- 敲除TSPO或使用PK11195可减轻小鼠肾损伤和纤维化。
- TSPO缺失通过抑制HK2糖酵解改善线粒体功能。
核心结论
- TSPO缺失通过破坏HK2介导的糖酵解并增强线粒体能量代谢,保护小鼠免受CKD进展中的肾损伤和肾小管间质纤维化。
研究设计与样本
- 使用小鼠单侧输尿管梗阻(UUO)和单侧缺血再灌注损伤(IRI)模型,以及肾小管特异性TSPO敲除小鼠(KspCreERT2; TSPOlox/lox)。
- 在TSPO缺陷的小鼠原代肾近端小管上皮细胞(RTECs)和人近端小管上皮细胞系(HK-2细胞)中研究低氧应激下的代谢能量代谢。
- 评估TSPO拮抗剂PK11195治疗对CKD小鼠的保护作用。
主要发现
- TSPO表达在CKD患者近端小管以及UUO和单侧IRI诱导的小鼠中增加。
- 肾小管特异性删除TSPO和PK11195治疗减轻了UUO或单侧IRI小鼠的肾损伤、炎症和纤维化。
- Bulk RNA-seq分析显示TSPO敲除小鼠肾脏中代谢通路基因富集,氧化磷酸化(OXPHOS)增加、糖酵解减少。
- 在低氧应激的原代RTECs中,TSPO缺失通过增强线粒体生物发生和膜电位、改善OXPHOS并减少糖酵解,从而增加ATP产生, preserved mitochondrial function。
- TSPO与糖酵解途径第一个酶己糖激酶2(HK2)在线粒体上相互作用,TSPO敲低触发HK2转位至胞质,从而降低糖酵解能力并改善线粒体稳态。
临床怎么用
- TSPO可能作为CKD进展的潜在治疗靶点,其拮抗剂PK11195在动物模型中显示出保护作用。
局限性
- 研究主要基于小鼠模型和细胞实验,尚未在人体临床试验中验证TSPO靶向治疗的有效性和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dysregulation of mitochondrial homeostasis is associated with kidney tubular injury and subsequent tubulointerstitial fibrosis, contributing to the development of chronic kidney diseases (CKD). Translocator protein (TSPO), located on the outer mitochondrial membrane, is upregulated in kidney tubules after injury; however, its roles in CKD progression remain unknown. METHODS: We investigated the impact of TSPO deficiency on mitochondrial dysfunction, kidney inflammation and fibrosis in mouse models of unilateral ureteral obstruction (UUO) and unilateral ischemia-reperfusion injury (IRI). Tubule-specific TSPO-knockout mice (KspCreERT2; TSPOlox/lox) were used. The role of TSPO in metabolic energy metabolism under hypoxic stress was delineated in TSPO-deficient primary renal proximal tubular epithelial cells (RTECs) from mice and in human proximal tubular epithelial cell line (HK-2 cells). The protective effect of TSPO antagonist PK11195 treatment was evaluated in mice with CKD. RESULTS: TSPO expression was increased in the proximal tubules of patients with CKD, and in UUO- and unilateral IRI-induced mice. Tubule-specific deletion of TSPO and treatment with PK11195 mitigated kidney injury, inflammation and fibrosis in UUO or unilateral IRI mice. Bulk RNA-seq analysis further revealed the enrichment of genes in metabolic pathways with increased oxidative phosphorylation (OXPHOS) and reduced glycolysis in kidneys from TSPO knockout mice. In primary RTECs subjected to hypoxic stress, deletion of TSPO preserved mitochondrial function by enhancing mitochondrial biogenesis and membrane potential, improving OXPHOS and reducing glycolysis, thereby increasing ATP production. Finally, TSPO interacted with the first enzyme of the glycolytic pathway, hexokinase 2 (HK2), on mitochondria, and TSPO knockdown triggered HK2 translocation to the cytosol, thereby decreasing its glycolytic capacity and improving mitochondrial homeostasis. CONCLUSIONS: TSPO depletion protected mice from kidney injury and tubulointerstitial fibrosis during CKD progression by disrupting HK2-mediated glycolysis and enhancing mitochondrial energy metabolism.
引用
- Feng Y, Yiu WH, Lam DK, et al. Translocator Protein and Mitochondrial Dysfunction in Chronic Kidney Disease. J Am Soc Nephrol. 2026. PMID: 42766371. doi:10.1681/ASN.0000001262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。